Table 4 CgA peptides according to the presence of arterial wall enhancement, of active TA and of vascular progression

Whole TA sample

No arterial wall enhancement (N = 25)

Arterial wall enhancement (N = 5)

p value

 CgA₄₃₉ (nM)

0.06 (0–0.62)

0.00 (0–0.78)

n.s.

 CgA-FRs (nM)

1.85 (0.39–5.03)

1.41 (0.32–3.93)

n.s.

 VS-1 (nM)

0.25 (0.02–1.15)

0.23 (0.10–0.79)

n.s.

 Rank CgA₄₃₉ + rank VS-1

38 (5–83)

36 (24–80)

n.s.

Patients on PPIs

No arterial wall enhancement (N = 20)

Arterial wall enhancement (N = 4)

p value

 CgA₄₃₉ (nM)

0.07 (0–0.62)

0.00 (0–0.78)

n.s.

 CgA-FRs (nM)

2.45 (0.41–5.03)

2.60 (1.25–3.93)

n.s.

 VS-1 (nM)

0.27 (0.06-1.15)

0.48 (0.22–0.79)

n.s.

 Rank CgA₄₃₉ + rank VS-1

44 (29–83)

32 (24–80)

n.s.

Hypertensive patients

No arterial wall enhancement (N = 13)

Arterial wall enhancement (N = 2)

p value

 CgA₄₃₉ (nM)

0.06 (0–0.62)

0.43 (0.09–0.78)

n.s.

 CgA-FRs (nM)

2.76 (0.77–5.03)

2.06 (0.32–3.8)

n.s.

 VS-1 (nM)

0.38 (0.17–1.15)

0.42 (0.10–0.74)

n.s.

 Rank CgA₄₃₉ + rank VS-1

50 (28–83)

58 (36–80)

n.s.

Whole TA sample

Inactive TA (N = 30)

Active TA (N = 12)

p value

 CgA₄₃₉ (nM)

0.05 (0–0.62)

0.03 (0–0.78)

n.s.

 CgA-FRs (nM)

1.37 (0.22–6.68)

1.80 (0.28–5.03)

n.s.

 VS-1 (nM)

0.19 (0.02–1.15)

0.21 (0.09–0.79)

n.s.

 Rank CgA₄₃₉ + rank VS-1

37 (5–83)

35 (18–80)

n.s.

Patients on PPIs

Inactive TA (N = 18)

Active TA (N = 12)

p value

 CgA₄₃₉ (nM)

0.08 (0–0.62)

0.03 (0–0.78)

n.s.

 CgA-FRs (nM)

2.55 (0.41–6.68)

1.80 (0.28–5.03)

n.s.

 VS-1 (nM)

0.32 (0.06–1.15)

0.21 (0.09–0.79)

n.s.

 Rank CgA₄₃₉ + rank VS-1

52 (24–83)

35 (18–80)

0.072

Hypertensive patients

Inactive TA (N = 15)

Active TA (N = 7)

p value

 CgA₄₃₉ (nM)

0.08 (0–0.62)

0.06 (0–0.78)

n.s.

 CgA-FRs (nM)

2.50 (0.22–6.68)

1.85 (0.28–5.03)

n.s.

 VS-1 (nM)

0.39 (0.05–1.15)

0.20 (0.09–0.74)

n.s.

 Rank CgA₄₃₉ + rank VS-1

50 (8–83)

39 (18–80)

n.s.

Whole TA sample

No vascular progression (N = 31)

Vascular progression (N = 9)

^p value

 CgA₄₃₉ (nM)

0.06 (0–0.78)

0 (0–0.14)

n.s.

 CgA-FRs (nM)

1.49 (0.22–5.03)

1.76 (0.32–4.24)

n.s.

 VS-1 (nM)

0.20 (0.02–1.15)

0.20 (0.09–0.79)

n.s.

 Rank CgA₄₃₉+ rank VS-1

42 (5–83)

36 (22–40)

n.s.

Patients on PPIs

No vascular progression (N = 20)

Vascular progression (N = 8)

p value

 CgA₄₃₉ (nM)

0.09 (0–0.78)

0 (0–0.14)

0.063

 CgA-FRs (nM)

2.45 (0.41–5.03)

1.81 (0.46–4.24)

n.s.

 VS-1 (nM)

0.27 (0.06–1.15)

0.21 (0.09–0.79)

n.s.

 Rank CgA₄₃₉ + rank VS-1

52 (24–83)

34.5 (22–40)

0.010

Hypertensive patients

No vascular progression (N = 16)

Vascular progression (N = 4)

p value

 CgA₄₃₉ (nM)

0.08 (0–0.78)

0.05 (0–0.14)

n.s.

 CgA-FRs (nM)

2.63 (0.22–5.03)

1.40 (0.32–4.24)

n.s.

 VS-1 (nM)

0.39 (0.05–1.15)

0.15 (0.09–0.37)

n.s.

 Rank CgA₄₃₉ + rank VS-1

52 (8–83)

33 (22–39)

0.050